Neurologische Langzeitfolgen von COVID-19

Benno Bremer; Christiana Franke

doi:10.1055/a-2335-0198

Fortschritte der Neurologie · Psychiatrie, Inhaltsverzeichnis

Fortschr Neurol Psychiatr 2024; 92(09): 362-377
DOI: 10.1055/a-2335-0198

Fort- und Weiterbildung

Neurologische Langzeitfolgen von COVID-19

Neurological long-term consequences of COVID-19

Benno Bremer

,

Christiana Franke

Abstract

Die COVID-19-Pandemie hat den öffentlichen Gesundheitssektor vor ungeahnte Herausforderungen gestellt. Doch während die gesellschaftliche Belastung durch die akute Erkrankung abzunehmen scheint, ebben die Berichte über Langzeitfolgen nicht ab. Mitunter am häufigsten berichtet werden neurologische Beschwerden wie anhaltende Erschöpfung und Kognitionsstörungen. Der wissenschaftliche Kenntnisstand entwickelt sich rasant und erste Therapieansätze zeichnen sich ab. Doch noch immer sind viele Fragen offen.

The COVID-19 pandemic faced the public health sector with unprecedented challenges. While the immediate impact on society seems to diminish, reports of long-term health consequences persist. Among the most frequently reported symptoms are neurological complaints such as persistent fatigue and cognitive impairments. Scientific understanding is evolving rapidly, and first therapeutic approaches are emerging. However, many questions still remain unanswered.

Schlüsselwörter

COVID-19 - Post-COVID-19-Syndrom - Fatigue - kognitive Störung - SARS-CoV-2

Keywords

COVID-19 - Post COVID-19 condition - fatigue - cognitive impairment - SARS-CoV-2

Volltext

Referenzen

Literatur
1 Johns Hopkins University – Coronavirus Resource Center. COVID-19 Dashboard. 2023. Zugriff am 20. Dezember 2023 unter: https://coronavirus.jhu.edu/map.html
2 Ritschel N, Radbruch H, Herden C. et al. COVID-19: Auswirkungen auf das zentrale und periphere Nervensystem. Pathologe 2021; 42: 172-182
3 Misra S, Kolappa K, Prasad M. et al. Frequency of neurologic manifestations in COVID-19: a systematic review and meta-analysis. Neurology 2021; 97: e2269-e2281
4 Alberti P, Beretta S, Piatti M. et al. Guillain-Barré syndrome related to COVID-19 infection. Neurol-Neuroimmunol 2020; 7: e741
5 Arnaud S, Budowski C, Ng Wing Tin S. et al. Post SARS-CoV-2 Guillain-Barre syndrome. Clin Neurophysiol 2020; 131: 1652-1654
6 Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S. et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology 2020; 95: e601-e605
7 Toscano G, Palmerini F, Ravaglia S. et al. Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020; 382: 2574-2576
8 Chaumont H, Etienne P, Roze E. et al. Acute meningoencephalitis in a patient with COVID-19. Rev Neurol 2020; 176: 519-521
9 Duong L, Xu P, Liu A. Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020. Brain Behav Immun 2020; 87: 33
10 Moriguchi T, Harii N, Goto J. et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 2020; 94: 55-58
11 Pilotto A, Odolini S, Masciocchi S. et al. Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol 2020; 88: 423-427
12 Watson OJ, Barnsley G, Toor J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022; 22: 1293-1302
13 Soriano JB, Murthy S, Marshall JC. et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22: e102-e107
14 European Centre for Disease Prevention and Control. Prevalence of post COVID-19 condition symptoms: a systematic review and meta-analysis of cohort study data, stratified by recruitment setting. Stockholm: European Centre for Disease Prevention and Control. 2022
15 World Health Organization (WHO). Post COVID-19 condition (Long COVID). 2022 Zugriff am 22. Dezember 2023 unter: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition
16 AOK Bundesverband. Post-Covid-Erkrankungen: Wenige Betroffene aber lange Ausfallzeiten. 2023 Zugriff am 22. Dezember 2023 unter: https://www.aok.de/pp/bv/pm/post-covid-erkrankungen/
17 Techniker Krankenkasse. Zwei Jahre Corona-Pandemie: Wie geht es Deutschlands Beschäftigten?. 2022 Zugriff am 20. Dezember 2023 unter: https://www.tk.de/resource/blob/2130932/70a0d93d19f6444f06310379441bd046/gesundheitsreport-2022-data.pdf
18 Tsampasian V, Elghazaly H, Chattopadhyay R. et al. Risk factors associated with post−COVID-19 condition. JAMA Int Med 2023; 183: 566
19 Herman JD, Atyeo C, Zur Y. et al. Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases. Sci Transl Med 2023; 15: eadf6598
20 Lundberg-Morris L, Leach S, Xu Y. et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ 2023; 383: e076990
21 Joy G, Artico J, Kurdi H. et al. Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Cardiovasc Imaging 2021; 14: 2155-2166
22 Matheson AM, McIntosh MJ, Kooner HK. et al. Longitudinal follow-up of postacute COVID-19 syndrome: DLCOquality-of-life and MRI pulmonary gas-exchange abnormalities. Thorax 2023; 78: 418-421
23 Murata N, Yamada A, Fujito H. et al. Cardiovascular manifestations identified by multi-modality imaging in patients with long COVID. Front Cardiovasc Med 2022; 9: 968584
24 Remy-Jardin M, Duthoit L, Perez T. et al. Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: dual-energy CT (DECT) angiographic study in 55 patients. EClinicalMedicine 2021; 34: 100778
25 Altmann DM, Whettlock EM, Liu S. et al. The immunology of long COVID. Nat Rev Immunol 2023; 23: 618-634
26 Douaud G, Lee S, Alfaro-Almagro F. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 2022; 604: 697-707
27 Frosolini A, Parrino D, Fabbris C. et al. Magnetic resonance imaging confirmed olfactory bulb reduction in long COVID-19: Literature review and case series. Brain Sci 2022; 12: 430
28 Blazhenets G, Schroeter N, Bormann T. et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med 2021; 62: 910-915
29 Díez-Cirarda M, Yus M, Gómez-Ruiz N. et al. Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. Brain 2023; 146: 2142-2152
30 Etter MM, Martins TA, Kulsvehagen L. et al. Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study. Nat Commun 2022; 13: 6777
31 Conway EM, Mackman N, Warren RQ. et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immun 2022; 22: 639-649
32 Lee M-H, Perl DP, Nair G. et al. Microvascular injury in the brains of patients with Covid-19. N Engl J Med 2020; 384: 481-483
33 Emmenegger M, Kumar SS, Emmenegger V. et al. Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins. PLOS Pathogens 2021; 17: e1010118
34 Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J 2022; 479: 537-559
35 Pretorius E, Venter C, Laubscher GJ. et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol 2022; 21: 148
36 Cheung CCL, Goh D, Lim X. et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 2022; 71: 226-229
37 Swank Z, Senussi Y, Manickas-Hill Z. et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis 2023; 76: e487-e490
38 Stein SR, Ramelli SC, Grazioli A. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 2022; 612: 758-763
39 Gold JE, Okyay RA, Licht WE. et al. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens 2021; 10: 763
40 Su Y, Yuan D, Chen DG. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185: 881-895e820
41 Zubchenko S, Kril I, Nadizhko O. et al. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int 2022; 42: 1523-1530
42 Franke C, Ferse C, Kreye J. et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun 2021; 93: 415-419
43 Richter AG, Shields AM, Karim A. et al. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol 2021; 205: 99-105
44 Son K, Jamil R, Chowdhury A. et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVIDsymptoms. Eur Respir J 2023; 61: 2200970
45 Song E, Bartley CM, Chow RD. et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med 2021; 2: 100288
46 Wallukat G, Hohberger B, Wenzel K. et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021; 4: 100100
47 Zuo Y, Estes SK, Ali RA. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020; 12: eabd3876
48 Franke C, Boesl F, Goereci Y. et al. Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behav Immun 2023; 109: 139-143
49 Monje M, Iwasaki A. The neurobiology of long COVID. Neuron 2022; 110: 3484-3496
50 Alkodaymi MS, Omrani OA, Fawzy NA. et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect 2022; 28: 657-666
51 Lopez-Leon S, Wegman-Ostrosky T, Perelman C. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11: 16144
52 Subramanian A, Nirantharakumar K, Hughes S. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med 2022; 28: 1706-1714
53 Ballering AV, Van Zon SKR, Olde Hartman TC. et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 2022; 400: 452-461
54 Premraj L, Kannapadi NV, Briggs J. et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci 2022; 434: 120162
55 Ceban F, Ling S, Lui LMW. et al. Fatigue and cognitive impairment in Post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun 2022; 101: 93-135
56 Boesl F, Audebert H, Endres M. et al. A neurological outpatient clinic for patients with post-COVID-19 syndrome – a report on the clinical presentations of the first 100 patients. Front Neurol 2021; 12: 738405
57 Schou TM, Joca S, Wegener G. et al. Psychiatric and neuropsychiatric sequelae of COVID-19 – a systematic review. Brain Behav Immun 2021; 97: 328-348
58 Franke C, Warnke C, Gorsler A. et al. Neurologische Manifestationen bei Patienten mit Post-COVID-19-Syndrom. DGNeurologie 2021; 4: 276-280
59 Berlit P, Bösel J, Franke C. et al. Neurologische Manifestationen bei COVID-19, S2k-Leitlinie. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. 2022 Zugriff am 22. Dezember 2023 unter: https://www.dgn.org/leitlinien
60 Franke C, Warnke C, Gorsler A. et al. Neurologische Manifestationen bei Patienten mit Post-COVID-19-Syndrom. DGNeurologie inAnlehnung an 2021; 4: 276-280
61 Nasreddine ZS, Phillips NA, Bédirian V. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699
62 Deuschl G, Maier W. S3-Leitlinie Demenzen. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. 2016 Zugriff am 22. Dezember 2023 unter: https://www.dgn.org/leitlinien
63 Nacul L, Authier FJ, Scheibenbogen C. et al. European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): expert consensus on the diagnosis, service provision, and care of people with ME/CFS in Europe. Medicina 2021; 57: 510
64 Krupp LB. The fatigue severity scale. Arch Neurol 1989; 46: 1121
65 Jackson C. The chalder fatigue scale (CFQ 11). Occup Med 2015; 65: 86-86
66 Guenther S, Loebel M, Mooslechner AA. et al. Frequent IgG subclass and mannose binding lectin deficiency in patients with chronic fatigue syndrome. Hum Immunol 2015; 76: 729-735
67 Carruthers BM, Jain AK, De Meirleir KL. et al. Myalgic encephalomyelitis/chronic fatigue syndrome. J Chronic Fatigue Syndr 2003; 11: 7-115
68 Khan AM, Piccirillo J, Kallogjeri D. et al. Efficacy of combined visual-olfactory training with patient-preferred scents as treatment for patients with COVID-19 resultant olfactory loss. JAMA Otolaryngol Head Neck Surg 2023; 149: 141
69 Ghali A, Lacombe V, Ravaiau C. et al. The relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome. J Transl Med 2023; 21: 375
70 Parker M, Sawant HB, Flannery T. et al. Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome. J Med Virol 2023; 95: e28373
71 Rosenfeld MJ. H.E.L.P. JAMA 1985; 253: 2043
72 Fox T, Hunt BJ, Ariens RAS. et al. Plasmapheresis to remove amyloid fibrin(ogen) particles for treating the post-COVID-19 condition. Cochrane Database Syst Rev 2023; 7: CD015775
73 Achleitner M, Steenblock C, Dänhardt J. et al. Clinical improvement of Long-COVID is associated with reduction in autoantibodies,lipids, and inflammation following therapeutic apheresis. Mol Psychiatry 2023; 28: 2872-2877
74 Ludwig B, Olbert E, Trimmel K. et al. The overview on current evidence for the treatment of ME/CFS is based on the principles of scientific assessment. Nervenarzt 2023; 94: 738-740
75 Brazier JE, Harper R, Jones NM. et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160-164
76 Tarlov AR. The medical outcomes study. JAMA 1989; 262: 925
77 Stein E, Heindrich C, Wittke K. et al. Observational study of repeat immunoadsorption (RIA) in Post-COVID ME/CFS patients with elevated β2-adrenergic receptor autoantibodies—an interim report. J Clin Med 2023; 12: 6428
78 Gottfried I, Schottlender N, Ashery U. Hyperbaric oxygen treatment—from mechanisms to cognitive improvement. Biomolecules 2021; 11: 1520
79 Tal S, Hadanny A, Sasson E. et al. Hyperbaric oxygen therapy can induce angiogenesis and regeneration of nerve fibers in traumatic brain injury patients. Front Hum Neurosci 2017; 11: 508
80 Zilberman-Itskovich S, Catalogna M, Sasson E. et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep 2022; 12: 11252
81 Rus CP, de Vries BEK, de Vries IEJ. et al. Treatment of 95 post-Covid patients with SSRIs. Sci Rep 2023; 13: 18599
82 Mazza MG, Zanardi R, Palladini M. et al. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol 2022; 54: 1-6
83 Macaya RF, Schultze P, Smith FW. et al. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci 1993; 90: 3745-3749
84 Weisshoff H, Krylova O, Nikolenko H. et al. Aptamer BC 007 – efficient binder of spreading-crucial SARS-CoV-2 proteins. Heliyon 2020; 6: e05421
85 Markham A, Duggan S. Vericiguat: First approval. Drugs 2021; 81: 721-726
86 O'Kelly B, Vidal L, McHugh T. et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun 2022; 24: 100485
87 Mateu L, Tebe C, Loste C. et al. Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study. Lancet Reg Health Eur 2023; 33: 100724
88 Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand 2022; 145: 5-9
89 Sriwastava S, Sharma K, Khalid S. et al. COVID-19 Vaccination and neurological manifestations: a review of case reports and case series. Brain Sci 2022; 12: 407
90 Klugar M, Riad A, Mekhemar M. et al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology 2021; 10: 752
91 Scholkmann F, May C-A. COVID-19, post-acute COVID-19 syndrome (PACS, “long COVID”) and post-COVID-19 vaccination syndrome (PCVS, “post-COVIDvac-syndrome”): similarities and differences. Pathol Res Pract 2023; 246: 154497
92 Riad A, Pokorná A, Attia S. et al. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med 2021; 10: 1428